Tumor-associated antigens - Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation - page 159

[34] Gannage M, Abel M, Michallet AS, Delluc S, Lambert M, Giraudier S, et al. Ex vivo
characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic
myeloid leukemia: implications for vaccine development and adoptive cellular immu-
notherapy. J Immunol 2005;174:8210-8.
[35] Kokhaei P, Palma M, Hansson L, Osterborg A, Mellstedt H, Choudhury A. Telomerase
(hTERT 611-626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and
generates spontaneously antileukemic, cytotoxic T cells. Exp Hematol 2007;35:297-304.
[36] van Baren N, Chambost H, Ferrant A, Michaux L, Ikeda H, Millard I, et al. PRAME, a
gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is
expressed in acute leukaemia cells. Br J Haematol 1998;102:1376-9.
[37] Ikeda H, Lethe B, Lehmann F, van Baren N, Baurain JF, de Smet C, et al. Characteriza-
tion of an antigen that is recognized on a melanoma showing partial HLA loss by CTL
expressing an NK inhibitory receptor. Immunity 1997;6:199-208.
[38] Santamaria CM, Chillon MC, Garcia-Sanz R, Perez C, Caballero MD, Ramos F, et al.
Molecular stratification model for prognosis in cytogenetically normal acute myeloid
leukemia. Blood 2009;114:148-52.
[39] Radich JP, Dai H, Mao M, Oehler V, Schelter J, Druker B, et al. Gene expression changes
associated with progression and response in chronic myeloid leukemia. Proc Natl Acad
Sci U S A 2006;103:2794-9.
[40] Kessler JH, Beekman NJ, Bres-Vloemans SA, Verdijk P, van Veelen PA, Kloosterman-
Joosten AM, et al. Efficient identification of novel HLA-A(*)0201-presented cytotoxic T
lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-
mediated digestion analysis. J Exp Med 2001;193:73-88.
[41] Griffioen M, Kessler JH, Borghi M, van Soest RA, van der Minne CE, Nouta J, et al.
Detection and functional analysis of CD8 + T cells specific for PRAME: a target for T-cell
therapy. Clin Cancer Res 2006;12:3130-6.
[42] Morita Y, Heike Y, Kawakami M, Miura O, Nakatsuka S, Ebisawa M, et al. Monitoring of
WT1-specific cytotoxic T lymphocytes after allogeneic hematopoietic stem cell trans-
plantation. Int J Cancer 2006;119:1360-7.
[43] Quintarelli C, Dotti G, De Angelis B, Hoyos V, Mims M, Luciano L, et al. Cytotoxic T lym-
phocytes directed to the preferentially expressed antigen of melanoma (PRAME) target
chronic myeloid leukemia. Blood 2008;112:1876-85.
[44] Rezvani K, Yong AS, Tawab A, Jafarpour B, Eniafe R, Mielke S, et al. Ex vivo character-
ization of polyclonal memory CD8 + T-cell responses to PRAME-specific peptides in
patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia.
Blood 2009;113:2245-55.
[45] Nishikawa H, Maeda Y, Ishida T, Gnjatic S, Sato E, Mori F, et al. Cancer/testis anti-
gens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma. Blood
2012;119(13):3097-104.
[46] Loncaster JA, Harris AL, Davidson SE, Logue JP, Hunter RD, Wycoff CC, et al. Carbonic
anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations
with tumor oxygen measurements and prognosis in locally advanced carcinoma of the
cervix. Cancer Res 2001;61:6394-9.
[47] Greiner J, Ringhoffer M, Taniguchi M, Li L, Schmitt A, Shiku H, et al. mRNA expression
of leukemia-associated antigens in patients with acute myeloid leukemia for the devel-
opment of specific immunotherapies. Int J Cancer 2004;108:704-11.
[48] Greiner J, Schmitt M, Li L, Giannopoulos K, Bosch K, Schmitt A, et al. Expression of
tumor-associated antigens in acute myeloid leukemia: implications for specific immu-
notherapeutic approaches. Blood 2006;108:4109-17.
[49] Li G, Passebosc-Faure K, Lambert C, Gentil-Perret A, Blanc F, Oosterwijk E, et al. The
expression of G250/mn/CA9 antigen by flow cytometry: its possible implication for
detection of micrometastatic renal cancer cells. Clin Cancer Res 2001;7:89-92.
[50] Brouwers AH, Mulders PF, Oyen WJ. Carbonic anhydrase IX expression in clear cell
renal cell carcinoma and normal tissues: experiences from (radio) immunotherapy.
J Clin Oncol 2008;26:3808-9; author reply 3811-12.
[51] Vissers JL, De Vries IJ, Schreurs MW, Engelen LP, Oosterwijk E, Figdor CG, et al. The
renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen
(HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes. Cancer Res
1999;59:5554-9.
[52] Herbert N, Haferkamp A, Schmitz-Winnenthal HF, Zoller M. Concomitant tumor
and autoantigen vaccination supports renal cell carcinoma rejection. J Immunol
2010;185:902-16.
[53] Su Z, Dannull J, Heiser A, Yancey D, Pruitt S, Madden J, et al. Immunological and clini-
cal responses in metastatic renal cancer patients vaccinated with tumor RNA-transfect-
ed dendritic cells. Cancer Res 2003;63:2127-33.

161